SLC5A2 and diabetes mellitus: The 2021 European Society of Cardiology (ESC) Diabetes Guidelines designate SGLT2 inhibitors as the primary recommended medication for individuals with diabetes who also have a concomitant high or very high cardiovascular risk, with a recommendation grade of IA.